Liminal BioSciences Inc.
LMNLNASDAQHealthcare
$8.50
+$0.01(+0.12%)
Market Cap$27621005
P/E Ratio—
52W High$8.5
52W Low$3.1
Liminal BioSciences Inc. (LMNL) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
LMNL · earnings · updated Jun 9, 2026
Latest Earnings
Q3 FY2023Report Date: Aug 8, 2023EPS Actual
$2.15
Revenue
$0.00B
Fiscal Period
Q3 FY2023
FY ends December
Report Date
Aug 8, 2023
After Market Close
✓ 1-Quarter EPS Beat Streak
LMNL reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.01B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.01B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2024 | Aug 6, 2024 | — | — | — | — | — | — |
| ◌ Q2 FY2024 | May 7, 2024 | — | — | — | — | — | — |
| ◌ Q1 FY2024 | Mar 13, 2024 | — | — | — | — | — | — |
| ◌ Q4 FY2023 | Nov 8, 2023 | — | — | — | — | — | — |
| — Q3 FY2023 | Aug 8, 2023 | — | $2.15 | — | $0.00B | — | — |
| — Q2 FY2023 | May 9, 2023 | — | $1.81 | — | $0.00B | — | — |
| — Q1 FY2023 | Mar 15, 2023 | — | $1.70 | — | $0.00B | — | — |
| — Q4 FY2022 | Nov 9, 2022 | — | $1.10 | — | $0.00B | — | — |
Q3 FY2024
Aug 6, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q2 FY2024
May 7, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q1 FY2024
Mar 13, 2024
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q4 FY2023
Nov 8, 2023
EPS Actual
—
EPS Est.
—
EPS Surpr.
—
Revenue
—
Q3 FY2023
Aug 8, 2023
EPS Actual
$2.15
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q2 FY2023
May 9, 2023
EPS Actual
$1.81
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q1 FY2023
Mar 15, 2023
EPS Actual
$1.70
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
Q4 FY2022
Nov 9, 2022
EPS Actual
$1.10
EPS Est.
—
EPS Surpr.
—
Revenue
$0.00B
No analyst estimates available for LMNL.
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| — Q3 FY2023 | Aug 8, 2023 | — | $8.37 | $8.37 | +0.00% |
| — Q2 FY2023 | May 9, 2023 | — | $6.78 | $6.77 | -0.15% |
| — Q1 FY2023 | Mar 15, 2023 | — | $5.19 | $4.52 | -12.91% |
| — Q4 FY2022 | Nov 9, 2022 | — | $5.05 | $4.95 | -1.98% |
| — Q3 FY2022 | Aug 9, 2022 | — | $5.20 | $5.00 | -3.85% |
| — Q2 FY2022 | May 10, 2022 | — | $6.53 | $6.34 | -2.91% |
| ▲ Q1 FY2022 | Mar 17, 2022 | +35.3% | $8.50 | $8.63 | +1.53% |
| ▼ Q4 FY2021 | Nov 15, 2021 | -7.1% | $16.00 | $16.00 | +0.00% |
Q3 FY2023+0.00%
Report Date
Aug 8, 2023
EPS Beat/Miss
—
Price Before
$8.37
Price After
$8.37
Q2 FY2023-0.15%
Report Date
May 9, 2023
EPS Beat/Miss
—
Price Before
$6.78
Price After
$6.77
Q1 FY2023-12.91%
Report Date
Mar 15, 2023
EPS Beat/Miss
—
Price Before
$5.19
Price After
$4.52
Q4 FY2022-1.98%
Report Date
Nov 9, 2022
EPS Beat/Miss
—
Price Before
$5.05
Price After
$4.95
Q3 FY2022-3.85%
Report Date
Aug 9, 2022
EPS Beat/Miss
—
Price Before
$5.20
Price After
$5.00
Q2 FY2022-2.91%
Report Date
May 10, 2022
EPS Beat/Miss
—
Price Before
$6.53
Price After
$6.34
Q1 FY2022+1.53%
Report Date
Mar 17, 2022
EPS Beat/Miss
+35.3%
Price Before
$8.50
Price After
$8.63
Q4 FY2021+0.00%
Report Date
Nov 15, 2021
EPS Beat/Miss
-7.1%
Price Before
$16.00
Price After
$16.00
Avg Beat Reaction+1.53%
Avg Miss Reaction+0.00%
Beat Rate1 / 8 quarters
Largest Move-12.91% (Q1 FY2023)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: LMNL ends December
Liminal BioSciences Inc. (LMNL) most recently reported earnings on August 8, 2023 for Q3 FY2023, posting EPS of $2.15 (in line with the analyst consensus of —). The next LMNL earnings date is expected around September 1, 2026.
Each quarter, investors track LMNL earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. LMNL revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
LMNL's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
LMNL earnings · 4 questionsLiminal BioSciences Inc.'s next earnings report is expected around September 1, 2026. LMNL typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; LMNL historically reports after market close (AMC).
LMNL earnings datewhen is LMNL earningsLMNL next earnings datewhen does LMNL report earningsLMNL earnings calendar
▸ Source: FMP · Liminal BioSciences Inc. SEC filings · US GAAP · Liminal BioSciences Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026